GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Forward PE Ratio

Exact Sciences (STU:EXK) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Forward PE Ratio?

Exact Sciences's Forward PE Ratio for today is 0.00.

Exact Sciences's PE Ratio without NRI for today is 0.00.

Exact Sciences's PE Ratio for today is 0.00.


Exact Sciences Forward PE Ratio Historical Data

The historical data trend for Exact Sciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Forward PE Ratio Chart

Exact Sciences Annual Data
Trend
Forward PE Ratio

Exact Sciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Exact Sciences's Forward PE Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Forward PE Ratio falls into.



Exact Sciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Exact Sciences  (STU:EXK) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Exact Sciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences (STU:EXK) Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.